Free Newsletter
Companies sue over generic Prevacid SoluTab
Ethypharm, Takeda, and TAP Pharmaceuticals are suing Barr Pharmaceuticals for patent infringement. The suit is over Barr's plan to market a generic version of Prevacid SoluTab tablets, the popular delayed-release heartburn drug that dissolves without water. The drug had sales of over $400 million in the last year in the U.S. alone.
Barr went to the Food and Drug Administration to request approval of a generic version of Prevacid late last year, but the plaintiffs are hoping to block the approval, which they claim violate patents set to expire in 2012 and 2019. At the same time, Barr shares appear to be on a downward trend, falling 34 cents on Tuesday. Takeda stock also fell in Japan.
- see the story at Forbes
- find out more at CNN Money
Related Articles:
Heartburn drug use in kids skyrockets
Pharma faces "tidal wave" of generics
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: